AbbVie’s Final Phase 3 MIRASOL Data Confirms 32% Reduced Risk of Death with ELAHERE in Platinum-Resistant Ovarian Cancer

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with E...

March 17, 2025 | Monday | News
Laplace Interventional Secures Series C Financing to Advance Transcatheter Tricuspid Valve Technology

The Series C financing was led by a global strategic investor along with participation from new investors Aphelion Cardeation and Unorthodox Ventures. Ex...

March 17, 2025 | Monday | News
Dr. Reddy’s Recalls Levetiracetam Injection in the U.S. Due to Mislabeled Infusion Bags

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “D...

March 14, 2025 | Friday | News
CervoMed Reports Positive 16-Week Extension Results for Neflamapimod in Lewy Body Dementia

CervoMed Inc. a clinical-stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), announced positive ...

March 11, 2025 | Tuesday | News
Enzene India Secures EU GMP Certification for Pune Facilities, Strengthening Global Biologics Manufacturing

Enzene, a pioneer in fully-connected continuous biologics manufacturing technology, today announced that its two facilities in Pune have received Europea...

March 05, 2025 | Wednesday | News
Avecho Biotechnology Partners with Sandoz for Exclusive Australian Rights to CBD Insomnia Capsule

Avecho Biotechnology Limited  announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG ("Sandoz") for th...

March 04, 2025 | Tuesday | News
Jasper Therapeutics Presents Promising Updated Data on Briquilimab for Mast Cell-Driven Diseases at AAAAI 2025

Jasper Therapeutics, Inc. (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit ...

March 03, 2025 | Monday | News
Nxera Pharma Signs Agreement with Viatris and Idorsia for Cenerimod Development and Commercialization in Japan, South Korea, and APAC

Nxera Pharma has entered an assignment agreement with Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Pharmaceuticals Ltd (&...

February 28, 2025 | Friday | News
European Commission Grants Conditional Marketing Authorization for Gilead’s Seladelpar in Primary Biliary Cholangitis

Gilead Sciences, Inc. announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of prima...

February 21, 2025 | Friday | News
GSK Announces China’s Acceptance of New Drug Application for Nucala (Mepolizumab) as COPD Treatment

GSK plc announced that the China National Medical Products Administration has accepted for review the new drug application for the use of Nucala ...

February 21, 2025 | Friday | News
Biogen and Stoke Therapeutics Collaborate on Zorevunersen for Dravet Syndrome Treatment

Biogen Inc.  and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...

February 19, 2025 | Wednesday | News
Rznomics’ RZ-001 Receives Fast Track Designation from FDA for Hepatocellular Carcinoma Treatment

Rznomics announced on the 14th that its anticancer drug, RZ-001, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for t...

February 18, 2025 | Tuesday | News
TAHO Pharmaceuticals Announces Positive Preliminary Results for TAH3311, World’s First Oral Resolution Film of Apixaban

TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first oral resolution film (ODF) of apixaban. Th...

February 18, 2025 | Tuesday | News
Zoetis Receives USDA Conditional License for Avian Influenza Vaccine for Chickens

Zoetis announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its...

February 17, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close